Market Currents
Phase IIb data that Sarepta Therapeutics (SRPT +2.9% to $27.88) presented over the weekend shows...
-
Monday, October 15, 2012, 9:38 AM ETPhase IIb data that Sarepta Therapeutics (SRPT +2.9% to $27.88) presented over the weekend shows that its eteplirsen treatment for Duchenne Muscular Dystrophy is effective. Piper Jaffray says the drug has the potential for accelerated approval and reiterates its Overweight rating on Sarepta with a $38 price target.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
